関連する実験動画
Updated: Sep 10, 2025

08:16
Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
6.8K
JAK/STATの謎は,変異異異質性,免疫欠陥,そして標的治療の出現
Durmus Burak Demirkaya1,2,3, Burkay Cagan Colak1,2,3, Asena Pinar Sefer4
1Division of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Türkiye.
Expert review of clinical immunology
|August 22, 2025
まとめ
ジャヌスキナーゼ/シグナルトランスデューサーおよびトランスクリプションアクティベーター (JAK/STAT) 経路の調節不良は免疫障害を引き起こす. これらのJAK/STAT経路の異常を理解することは,より良い患者の結果のための標的治療の開発の鍵です.
科学分野:
- 免疫学
- 分子生物学
- 遺伝学
背景:
- ジャヌスキナーゼ/シグナルトランスデューサーおよびトランスクリプションアクティベーター (JAK/STAT) 経路は,免疫調節,細胞増殖,分化およびアポトーシスを制御するために不可欠です.
- この経路の変異は 免疫の先天的な誤りや 免疫媒介性疾患につながる可能性があります
- JAK/STAT経路の機能障害の分子基礎を理解することは,正確な診断と効果的な治療の開発に不可欠です.
研究 の 目的:
- JAK/STAT信号経路の包括的な概要を提供すること.
- JAK/STATタンパク質の構造と機能について議論する.
- STAT1,STAT3およびSTAT6における機能獲得変異の免疫病理学的結果をレビューする.
主な方法:
- 2025年6月までのPubMedとMEDLINEで文献検索が行われました.
- このレビューは,JAK/STAT経路の調節と疾患メカニズムに関する情報をまとめています.
- JAK阻害剤 (JAKinibs) を含む臨床的進歩と治療戦略は批判的に評価されています.
主要な成果:
- STAT1,STAT3,STAT6の機能増強疾患は,免疫機能不調と関連しています.
- JAK阻害剤 (JAKinibs) は治療において大きな進歩を遂げました
- これらの疾患の管理には 分子洞察を臨床実践に統合することが不可欠です
結論:
- JAK/STAT経路の不調を理解することで 精密医療のアプローチが可能になった.
- JAKinibの治療法を最適化し,バイオマーカーを特定し,患者の選択を改善するためにさらなる研究が必要です.
- JAK/STAT関連疾患の管理に変化をもたらす新しい標的療法が期待されています.
関連する概念動画
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Mismatch Repair
5.2K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.2K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K

